Asset
DEFACTINIB
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02372227 | phase1 | terminated | 2015-01-01 | 2015-10-01 | Verastem, Inc. | A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma |
| NCT00787033 | phase1 | completed | 2008-12-01 | 2011-03-01 | Verastem, Inc. | A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies |
| NCT02004028 | phase2 | terminated | 2013-12-12 | 2019-06-19 | Verastem, Inc. | Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants |
FDA applications (0)
This company has no applications containing this asset.